ERBB2 and invasive ductal breast carcinoma: Pathology revealed a poorly differentiated infiltrating ductal carcinoma, estrogen receptor positive (ER+) 100%, progesterone receptor positive (PR+) 95%, and human epidermal growth factor receptor-2 (HER2) negative.